What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Efficacy and safety of azacitidine plus LDAC in newly diagnosed, frail elderly patients with Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Overall response rate was 50% in patients receiving azacitidine plus LDAC, indicating effective treatment.
Median overall survival was 22.5 months, highlighting significant longevity for frail elderly patients with AML.
This clinical trial evaluated the safety and efficacy of azacitidine and LDAC in a defined population of elderly patients.
The presence of key adverse events, like febrile neutropenia, emphasizes the need for careful monitoring during treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial demonstrates effective safety and efficacy of azacitidine in elderly AML patients, suggesting a viable treatment option for frail individuals.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d37e https://doi.org/10.1182/blood-2025-6983

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates effective safety and efficacy of azacitidine in elderly AML patients, suggesting a viable treatment option for frail individuals.

Efficacy and safety of azacitidine plus LDAC in newly diagnosed, frail elderly patients with Acute Myeloid Leukemia

Key Points

Discussion

Implication

Cite This Study

Efficacy and safety of azacitidine plus LDAC in newly diagnosed, frail elderly patients with Acute Myeloid Leukemia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider